Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Consensus Target Price of $15.40

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have earned a consensus rating of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $15.40.

A number of research firms recently weighed in on DRTS. HC Wainwright raised their price target on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Barclays upped their price objective on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Zacks Research lowered shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Finally, Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd.

Alpha Tau Medical Stock Up 1.7%

DRTS stock opened at $14.77 on Friday. The firm has a market capitalization of $1.33 billion, a PE ratio of -14.20 and a beta of 1.20. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. Alpha Tau Medical has a twelve month low of $3.43 and a twelve month high of $15.79. The stock’s 50 day moving average is $13.97 and its 200-day moving average is $10.88.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.36). Sell-side analysts expect that Alpha Tau Medical will post -1.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Alpha Tau Medical news, CFO Raphi Levy sold 2,871 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $15.00, for a total value of $43,065.00. Following the transaction, the chief financial officer owned 90,180 shares of the company’s stock, valued at approximately $1,352,700. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 62,871 shares of company stock worth $823,108 in the last 90 days. Company insiders own 39.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Everhart Financial Group Inc. purchased a new position in Alpha Tau Medical in the second quarter valued at about $126,000. Principal Financial Group Inc. bought a new position in shares of Alpha Tau Medical during the 1st quarter valued at approximately $132,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Alpha Tau Medical during the 1st quarter worth approximately $286,000. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based biotechnology and medical technology company developing targeted alpha radiation therapies for the treatment of solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses radium-224 sources placed into or near a tumor. As the radium decays, its short-range alpha-emitting products are intended to diffuse through the tumor and destroy cancer cells.